Helena Tavares de Sousa

Our new guideline streamlines #CrohnsDisease treatment. Early use of high-efficacy therapies can improve outcomes and reduce progression. Read more here: ow.ly/u5Rc50Xui9y @FrankIScottMD @AshwinMDIBD @BenClickMD @GauravsyalMD @JHaydek @MichaelKappel12 @JamesLewisGIEpi

#CCCongress25 #MECONIUM study 🔺First 1000 days of life 🔑 to 👶🏻immune develpmt 🔺🤰🏽gut microbiome =largest donor of 👶🏻 microbiome 🔺⬇️diversity, ⬆️FCP in 👶🏻of IBD moms 🔺Neg impact on 👶🏻 microbiome: abx, c/section, formula feeding #MELODY: + effect of AI diet in🤰 More info👇🏽

Webinar "Traga um problema, leve soluções" A 4ª Edição deste webinar decorrerá na próxima quarta-feira, dia 12 de fevereiro, às 21h30! 👉 Inscreva-se aqui: pt.surveymonkey.com/r/webinar_12fe… #GEDII #IBD #DoençasInflamatóriasIntestinais

Free access to the ECCO'25 Abstract book: 👇👇🏽👇🏿 ecco-ibd.eu/publications/c… @IBD_FloMD @fgomollon @Y_ECCO_IBD @Bealoquebea @alearmuzzi @fgomollon @anaguticasbas @ibdseb @AlaaEl_Hussuna @IBD_MB @RPanaccione @DignassAxel @I_Blumenstein @GianlucaPellino @bverstockt @DCharabaty

A Reunião Anual GEDII 2025 começa já amanhã! 🌟 Nesta edição, iremos celebrar de uma forma muito especial o 20º aniversário do Grupo. #GEDII20Anos #ReuniãoAnualGEDII #DoençasInflamatóriasIntestinais

Great First session in @GEDII_IBD about Early (diagnosis @JoanaTo62523004 ) (treatment @alearmuzzi ) (surgery @pakotze ) and @fgomollon been cited Time is the key in CD What about UC? My opinión “better early than late”

Risankizumab, IgG1, has lower than expected placental transfer rates with infant > mom. @MLongMD @PIANOIBD @UCSFHospitals Low Placental Transfer Rates of Risankizumab Among Pregnant Women With Inflammatory Bowel Disease academic.oup.com/ibdjournal/art…

THE RISK OF IBD IN OFFSPRING INCREASES IF EITHER PARENT HAS IBD BEFORE CHILDBIRTH 👩🏻👨🏾👶🏼 New Study in Gut shows that both maternal and paternal IBD diagnosis before childbirth is associated with higher IBD risk in offspring. Read the study here ➡️ gut.bmj.com/cgi/rapidpdf/g…

🔬New paper from #WeTheFibrosisLab🔬Deciphering the Differences Between Stricturing With or Without Penetrating Crohn's Disease: One Step Closer to Solving the Puzzle ⁦@MRegueiroMD⁩ ⁦@FernandoMagro6⁩ ⁦@pranab_IBD⁩ ⁦@JChandra_IBD⁩ @ pubmed.ncbi.nlm.nih.gov/39074176/

@IBD_FloMD @MRegueiroMD @FernandoMagro6 @pranab_IBD @JChandra_IBD What an honour to have such an Editorial! 🤩

Huge honour for me to have you @BettenworthDb and @JoanaTo62523004 as my PhD main jury. Unforgettable day! ❤️

Excellent overview on #perianal #crohnsdisease by @MiguelCunhaSurg

VIVID-1 h2h trial with mirikizumab vs ustekinumab in #CD ✅mirikizumab achieved non-inferiority to ustekinumab ❗️Be aware this is not like SEQUENCE! Patients here were around 50% previously exposed to AntiTNF whereas SEQUENCE all were previously exposed and the trial design and population are different!!!

Safety of lactation in women patients with #IBD and vaccination of infants born to mothers with IBD So much data to process throughout all this session with great content and summaries Fantastic @JulsgaardMette at @DDWMeeting #DDW2024

Fresh off the press! 📰 Can quantitative DWI assess inflammation & subsequent treatment response in Crohn's? Our very own @therealjonadill & colleagues address just that! doi.org/10.1007/s00261…

#GUTImages from the #RecentAdvancesInClinicalPractice paper by @IBD_FloMD et al entitled "Fibrosis in IBD: from pathogenesis to therapeutic targets" via bit.ly/4aLgTpO @CleClinicMD @pranab_IBD #Fibrosis #IBD

What a honour to work with this fantastic team and to have our research @JCC_IBD The best way to finish my PhD thesis 🤩@FernandoMagro6 #Fatima Carneiro @GulloIrene #Marta Ferreira # Ana Mafalda Rocha # Carla Oliveira

The PANTS-extension study out today @LancetGastroHep After 3 years of therapy only 1/3 IFX and 1/3 ADA patients are still on drug in remission • notable that proportion exiting due to drug failure higher with ADA versus IFX (remember this is NOT randomised h2h) Most important new insight with infliximab: • start AZA before or at the same time as IFX • use a full dose of AZA (at least early on) Dose intensification in the context of immunogenicity does not work for very long Very important learnings for clinical practice here to consider alongside @ProfileCrohn

New research - Chanchlani et al - Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn’s disease: 3-year data from the prospective, multicentre PANTS cohort study thelancet.com/journals/langa… #GITwitter #IBD